Core Laboratories Inc.
CLB
$13.36
$0.181.33%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 524.73M | 526.52M | 517.50M | 517.38M | 517.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 524.73M | 526.52M | 517.50M | 517.38M | 517.80M |
| Cost of Revenue | 420.19M | 417.59M | 414.27M | 416.17M | 415.40M |
| Gross Profit | 104.54M | 108.93M | 103.23M | 101.20M | 102.39M |
| SG&A Expenses | 45.23M | 44.23M | 42.70M | 40.65M | 40.46M |
| Depreciation & Amortization | 14.70M | 14.65M | 14.65M | 14.73M | 14.83M |
| Other Operating Expenses | -1.26M | -1.66M | -1.53M | -2.16M | -2.90M |
| Total Operating Expenses | 478.86M | 474.80M | 470.09M | 469.40M | 467.79M |
| Operating Income | 45.88M | 51.72M | 47.41M | 47.98M | 50.01M |
| Income Before Tax | 43.08M | 45.90M | 44.22M | 42.64M | 42.85M |
| Income Tax Expenses | 13.51M | 15.51M | 11.49M | 12.42M | 14.12M |
| Earnings from Continuing Operations | 29.57 | 30.39 | 32.73 | 30.21 | 28.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -535.00K | -722.00K | -607.00K | -581.00K | -706.00K |
| Net Income | 29.03M | 29.67M | 32.12M | 29.63M | 28.03M |
| EBIT | 45.88M | 51.72M | 47.41M | 47.98M | 50.01M |
| EBITDA | 60.57M | 66.37M | 62.06M | 62.71M | 64.83M |
| EPS Basic | 0.62 | 0.64 | 0.69 | 0.63 | 0.59 |
| Normalized Basic EPS | 0.44 | 0.52 | 0.45 | 0.46 | 0.48 |
| EPS Diluted | 0.61 | 0.62 | 0.67 | 0.62 | 0.59 |
| Normalized Diluted EPS | 0.43 | 0.51 | 0.45 | 0.46 | 0.47 |
| Average Basic Shares Outstanding | 185.67M | 186.37M | 187.44M | 188.10M | 188.38M |
| Average Diluted Shares Outstanding | 187.21M | 187.91M | 188.99M | 189.73M | 190.11M |
| Dividend Per Share | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 |
| Payout Ratio | 6.41% | 6.30% | 5.83% | 6.33% | 6.70% |